SALT LAKE CITY, January 30, 2018 – Elute, Inc., an emerging leader in developing a new class of polymer-controlled drug delivery devices designed to prevent and treat orthopedic and other surgical bone infections, announced today that the Company has received a notice of allowance from the United States Patent & Trademark Office on January 26th for its invention of “Implantable Devices for Bone or Joint Defects”.
“We are very pleased to receive this notification,” said Ashok C. Khandkar, Ph.D., Chief Executive Officer of Elute. “The scope of this patent enables us to maintain our advantage and protect the proprietary aspects of our technologies, as we move forward towards the clinical introduction of our products”, stated Dr. Khandkar.
The claims language gives Elute broad protection for the first combination drug/device producton the market capable of delivering an antibiotic for up to eight weeks to eradicate infection and grow new bone.
“This allowance is key to our strategy of aggressively pursuing patent coverage and enhancing value,” said Dennis B. Farrar, Executive Chairman and co-founder of Elute.
About Elute, Inc.™
Elute, Inc. is a private medical device company developing innovative polymer-controlled drug delivery devices designed to prevent and treat orthopedic and other surgical bone infections. Elute’s products provide a clinically relevant delivery of antibiotics and other therapeutic agents directly into surgical sites of patients undergoing orthopedic and other procedures. Elute’s first product candidate, EP Granules™, has demonstrated the controlled release of certain antibiotics in a therapeutic range for a 6-8-week period. The Company has assembled a strong management team, Board of Directors and Clinical Advisory Board with significant clinical and,commercial development experience. Elute, Inc. is located in Salt Lake City, Utah. For more information, please visit the Company’s website at www.elutinc.com.
Ashok C Khandkar, PhD,